A Phase 2 interventional study of Hyaluronidase and Histamine in Allergic Skin Reaction, sponsored by Amphastar Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-20.
Sponsored by Amphastar Pharmaceuticals, Inc. · Phase 2, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 301 studies in Hypersensitivity with a site in United States — 33 open to participants now, 41 under way, 1 of them phase 3. Hypersensitivity · United States.
Among the 301 studies in Hypersensitivity with a site in United States, this one is the 46th largest by enrollment of the 220 interventional ones that give a count, is one of 12 that started in 2012, is one of 49 in phase 2, and was the 146th registered.
1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.
Browse Hypersensitivity studies →33 of the 301 studies in Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 12+
Lumicell, Inc. · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–50
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12 mo–17 yrs
Qifeng Zhang · Sites in United States, China
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
301 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 63 · Phase 3 41 · Phase 4 18
First in 1996; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 253 is above the median of 73 across 692 interventional studies indexed under Hypersensitivity.
Median enrollment 60 across the 220 interventional studies, 199 across the 77 observational. Of the 243 that completed or were terminated, 104 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
117 of 301 have an industry lead sponsor. The 10 most frequent:
Amphastar Pharmaceuticals, Inc. is the lead sponsor of 21 studies on the registry; none are open to participants now.
Amphastar Pharmaceuticals, Inc. has 1 study filed under Hypersensitivity — fewer than ten, so there is no comparison to draw.
12 of the studies in Hypersensitivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT07447869National Institute of Allergy and Infectious Diseases (NIAID)LYmph Node eXamination in Cat Allergen Immunotherapy | 2027-01-27 |
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
| NCT06834165ARS Pharmaceuticals, Inc.Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy | 2027-04 |
Add all 12 to your calendar (.ics) → With an account.
Among the 301 studies in Hypersensitivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the allergenicity of Amphadase® in healthy volunteers using an intradermal skin test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy volunteers of either gender; Those without cardiovascular gastrointestinal, hepatic, neurological, psychiatric, endocrine, or other major systemic disease that would unduly risk the subject's safety or interfere with the interpretation of results, assessed according to the judgment of the Principal Investigator. A non-inclusive list which would not be exclusionary and define healthy individual for the purposes of this study are:
mild arthritic conditions if not taking excluded medications.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intradermal injection of Amphadase (hyaluronidase 150 USP units/mL)
Drug: Hyaluronidase
Intradermal injection of Histatrol (histamine base 0.1 mg/mL)
Drug: Histamine
Intradermal injection of saline (0.02 mL)
Drug: Saline
Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
Also known as: Amphadase®
Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
Also known as: Histatrol®
Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. A positive reaction consisted of: a) reaction appearing within 30 minutes of drug placement; b) wheal (\>8 mm) with or without pseudopods; c) reaction accompanying erythema; and d) reaction accompanying localized itching.
Time frame: Up to 30 minutes after the final study drug injection
Positive Allergic Reaction to Amphadase® in the Intent-to-Treat Population (ITT)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. A positive reaction consisted of: a) reaction appearing within 30 minutes of drug placement; b) wheal (\>8 mm) with or without pseudopods; c) reaction accompanying erythema; and d) reaction accompanying localized itching.
Time frame: Up to 30 minutes after the final study drug injection
Observed Wheal Size in the Per-Protocol Population (PPP)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed wheal size is the greatest wheal diameter measured at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Observed Erythema Size in the Per-Protocol Population (PPP)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed erythema size is the greatest erythema diameter measured at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Allergic Wheal Size in the Per-Protocol Population (PPP)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic wheal size is the greatest wheal diameter with accompanying erythema and localized itching measured at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Allergic Erythema Size in the Per-Protocol Population (PPP)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic erythema size is the greatest erythema diameter with accompanying localized itching measured at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Local Itchiness Rate in the Per-Protocol Population (PPP)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The local itchiness rate is the percentage of subjects that reported localized itching at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Erythema Responder Rate in the Per-Protocol Population (PPP)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The erythema responder rate is the percentage of subjects that showed an erythema reaction at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Observed Wheal Size in the Intent-to-Treat Population (ITT)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed wheal size is the greatest wheal diameter measured at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Observed Erythema Size in the Intent-to-Treat Population (ITT)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed erythema size is the greatest erythema diameter measured at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Allergic Erythema Size in the Intent-to-Treat Population (ITT)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic erythema size is the greatest erythema diameter with accompanying localized itching measured at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Local Itchiness Rate in the Intent-to-Treat Population (ITT)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The local itchiness rate is the percentage of subjects that reported localized itching at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Erythema Responder Rate in the Intent-to-Treat Population (ITT)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The erythema responder rate is the percentage of subjects that showed an erythema reaction at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
Allergic Wheal Size in the Intent-to-Treat Population (ITT)
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic wheal size is the greatest wheal diameter with accompanying erythema and localized itching measured at the injection site(s) for a specific study drug injection.
Time frame: Up to 30 minutes after the final study drug injection
| Milestone | H, N, H, P | H, N, P, H | H, P, H, N | H, P, N, H | N, H, H, P | N, H, P, H | P, H, H, N | P, H, N, H |
|---|---|---|---|---|---|---|---|---|
| Started | 32 | 32 | 32 | 31 | 31 | 31 | 32 | 32 |
| Completed | 32 | 31 | 32 | 31 | 31 | 31 | 32 | 32 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. A positive reaction consisted of: a) reaction appearing within 30 minutes of drug placement; b) wheal (\>8 mm) with or without pseudopods; c) reaction accompanying erythema; and d) reaction accompanying localized itching.
| participants | Per-Protocol Population (PPP) |
|---|---|
| Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP) | 0 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. A positive reaction consisted of: a) reaction appearing within 30 minutes of drug placement; b) wheal (\>8 mm) with or without pseudopods; c) reaction accompanying erythema; and d) reaction accompanying localized itching.
| participants | Intent-to-Treat Population (ITT) |
|---|---|
| Positive Allergic Reaction to Amphadase® in the Intent-to-Treat Population (ITT) | 7 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed wheal size is the greatest wheal diameter measured at the injection site(s) for a specific study drug injection.
| mm | Arm H | Arm N | Arm P |
|---|---|---|---|
| Observed Wheal Size in the Per-Protocol Population (PPP) | 1.1 ± 2.6 | 1.7 ± 2.7 | 15.3 ± 4.9 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed erythema size is the greatest erythema diameter measured at the injection site(s) for a specific study drug injection.
| mm | Arm H | Arm N | Arm P |
|---|---|---|---|
| Observed Erythema Size in the Per-Protocol Population (PPP) | 4.3 ± 7.0 | 0.6 ± 3.7 | 44.4 ± 11.7 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic wheal size is the greatest wheal diameter with accompanying erythema and localized itching measured at the injection site(s) for a specific study drug injection.
| mm | Arm H | Arm N | Arm P |
|---|---|---|---|
| Allergic Wheal Size in the Per-Protocol Population (PPP) | 0.1 ± 0.9 | 0.0 ± 0.0 | 15.2 ± 4.9 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic erythema size is the greatest erythema diameter with accompanying localized itching measured at the injection site(s) for a specific study drug injection.
| mm | Arm H | Arm N | Arm P |
|---|---|---|---|
| Allergic Erythema Size in the Per-Protocol Population (PPP) | 1.1 ± 5.0 | 0.0 ± 0.1 | 44.1 ± 11.8 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The local itchiness rate is the percentage of subjects that reported localized itching at the injection site(s) for a specific study drug injection.
| percentage of participants | Arm H | Arm N | Arm P |
|---|---|---|---|
| Local Itchiness Rate in the Per-Protocol Population (PPP) | 7.7 | 1.1 | 100.0 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The erythema responder rate is the percentage of subjects that showed an erythema reaction at the injection site(s) for a specific study drug injection.
| percentage of participants | Arm H | Arm N | Arm P |
|---|---|---|---|
| Erythema Responder Rate in the Per-Protocol Population (PPP) | 51.4 | 8.7 | 100.0 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed wheal size is the greatest wheal diameter measured at the injection site(s) for a specific study drug injection.
| mm | Arm H | Arm N | Arm P |
|---|---|---|---|
| Observed Wheal Size in the Intent-to-Treat Population (ITT) | 1.5 ± 3.3 | 1.7 ± 2.8 | 14.1 ± 5.6 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed erythema size is the greatest erythema diameter measured at the injection site(s) for a specific study drug injection.
| mm | Arm H | Arm N | Arm P |
|---|---|---|---|
| Observed Erythema Size in the Intent-to-Treat Population (ITT) | 5.4 ± 9.6 | 0.9 ± 4.5 | 41.5 ± 14.7 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic erythema size is the greatest erythema diameter with accompanying localized itching measured at the injection site(s) for a specific study drug injection.
| mm | Arm H | Arm N | Arm P |
|---|---|---|---|
| Allergic Erythema Size in the Intent-to-Treat Population (ITT) | 2.1 ± 8.0 | 0.1 ± 1.9 | 34.0 ± 21.1 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The local itchiness rate is the percentage of subjects that reported localized itching at the injection site(s) for a specific study drug injection.
| percentage of participants | Arm H | Arm N | Arm P |
|---|---|---|---|
| Local Itchiness Rate in the Intent-to-Treat Population (ITT) | 10.3 | 1.6 | 79.1 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The erythema responder rate is the percentage of subjects that showed an erythema reaction at the injection site(s) for a specific study drug injection.
| percentage of participants | Arm H | Arm N | Arm P |
|---|---|---|---|
| Erythema Responder Rate in the Intent-to-Treat Population (ITT) | 53.8 | 11.1 | 97.6 |
Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic wheal size is the greatest wheal diameter with accompanying erythema and localized itching measured at the injection site(s) for a specific study drug injection.
| mm | Arm H | Arm N | Arm P |
|---|---|---|---|
| Allergic Wheal Size in the Intent-to-Treat Population (ITT) | 0.5 ± 2.4 | 0.0 ± 0.7 | 11.5 ± 7.6 |
Collected over Signing of Informed Consent until Adverse Event Resolution/Stabilization (approximately 30 days). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm H | — | 0/253 (0%) | 0/253 (0%) |
| Arm N | — | 0/253 (0%) | 0/253 (0%) |
| Arm P | — | 0/253 (0%) | 0/253 (0%) |
| All Arms | — | 0/253 (0%) | 0/253 (0%) |
| Age, Categorical(Participants) | Total Study Population |
|---|---|
| <=18 years | 7 |
| Between 18 and 65 years | 239 |
| >=65 years | 7 |
| Age, Continuous(years) | Total Study Population |
|---|---|
| Mean | 34.9 ± 14.0 |
| Sex: Female, Male(Participants) | Total Study Population |
|---|---|
| Female | 127 |
| Male | 126 |
| Region of Enrollment(participants) | Total Study Population |
|---|---|
| United States | 253 |
Plan to share: No
The record gives a start of Sep 2012, a primary completion of Nov 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronoglucosaminidase
Amphastar Pharmaceuticals, Inc.